Company news

Cytokinetics, Incorporated news in 2021

Cytokinetics, Incorporated's news releases, calls and decks from 2021, newest first.

View company

Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics

December 19, 2021

Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND

December 9, 2021

Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten

December 8, 2021

Cytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND

November 29, 2021

Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021

November 14, 2021

Cytokinetics Announces Two Presentations at the AHA Scientific Sessions 2021

November 7, 2021

Cytokinetics Reports Third Quarter 2021 Financial Results

November 2, 2021

Cytokinetics Announces Preclinical Data for CK-3828136 to Be Presented at the 2021 Medicinal Chemistry Gordon Research Conference

October 20, 2021

Cytokinetics to Announce Third Quarter Results on November 3, 2021

October 19, 2021

Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day

October 6, 2021

Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals

September 27, 2021

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

September 11, 2021

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting

August 30, 2021

Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA

August 18, 2021

Cytokinetics Reports Second Quarter 2021 Financial Results

August 4, 2021

Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis

August 1, 2021

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 22, 2021

Cytokinetics to Announce Second Quarter Results on August 5, 2021

July 21, 2021

Cytokinetics Announces Positive Topline Results of Redwood-HCM

July 18, 2021

Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021

June 29, 2021

Cytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress

June 22, 2021

Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction

June 14, 2021

Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology

May 16, 2021

Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)

May 15, 2021

Cytokinetics Reports First Quarter 2021 Financial Results

May 5, 2021

Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment

May 3, 2021

Cytokinetics to Announce First Quarter Results on May 6, 2021

April 21, 2021

Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting

April 11, 2021

Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting

April 1, 2021

Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)

March 17, 2021

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 25, 2021

Cytokinetics Reports Fourth Quarter 2020 Financial Results

February 24, 2021

Cytokinetics Names Muna Bhanji to Board of Directors

February 17, 2021

Cytokinetics to Announce Fourth Quarter Results on February 25, 2021

February 10, 2021

Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants

February 1, 2021

Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM

January 12, 2021

Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy

January 10, 2021

Calls in 2021

Decks in 2021